Merck & Co says long-term cholesterol drug study met primary endpoint

Merck said that its long-term Improve-It trial, which was aimed at showing whether its Zetia and Vytorin franchise does more than reduce "bad" cholesterol.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news